

Elimusertib enhances cytotoxic effects of conventional chemotherapy and sensitizes to radiation in preclinical Ewing sarcoma models

Leonhard Koch^{123*}, Maximilian Kerkhoff¹²³, Maximilian Bretschneider¹²³, Samet Dayi¹²³, Pauline Plaumann¹²³, Emma Maaßen¹²³, Emilia Hillesheim¹²³, Marc Kuballa¹²³, Christiane Schaefer¹²³, Daniel Rauh⁴, Susanne Grunewald²³, Sebastian Bauer²³, Cläre von Neubeck⁵, Uta Dirksen^{123*}

¹ Department of Pediatrics III, University Hospital Essen, Essen, Germany

² West German Cancer Center Essen, University Hospital Essen, Essen, Germany

³ German Cancer Consortium (DKTK), National Center for Tumordiseases (NCT) west, partner site Essen, Germany


⁴ Faculty of Chemistry and Chemical Biology, TU Dortmund, Dortmund, Germany

⁵ Department of Particle Therapy, University Hospital Essen, Essen, Germany

*Corresponding Authors; leonhard.koch@uk-essen.de; uta.dirksen@uk-essen.de

SUPPLEMENTARY MATERIAL:


S1: Cell viability assay and IC₅₀ values of elimusertib




S2: Cell viability assays and IC₅₀ values of other ATR inhibitors


		IC ₅₀ -concentration (nM)			
		Elimusertib	Berzosertib	Ceralasertib	AZ-20
cell line	EW-7	10	36	201	103
	STA-ET-1	13	33	113	50
	TC-71	35	33	228	149

S3: Original western blot from Fig. 1 D with labeling





S4: Raw full images from Fig 1 D without labeling





S5: Original western blots from Fig. 3 C with labeling; cell line EW-7





S6: Raw full images from Fig. 3 C without labeling

